Calando Pharmaceuticals, Inc. Announces Completion of IT-101 Phase 1 Clinical Study

PASADENA, Calif.--(BUSINESS WIRE)--Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today completion of the IT-101 Phase I clinical study conducted at City of Hope in Duarte, California. The company expects the entire study data to be published in early 2009. IT-101 is an experimental, nanoparticle therapeutic that consists of the drug camptothecin (CPT) conjugated to a cyclodextrin polymer. IT-101, the first drug candidate in Calando’s proprietary CyclosertTM pipeline, has now successfully completed a Phase I trial designed to evaluate its safety, tolerability, and pharmacokinetics in patients with inoperable or metastatic tumors.

Back to news